Drug Profile
Olipudase alfa - Sanofi
Alternative Names: Acid sphingomyelinase Niemann Pick disease type B - Sanofi; Acid-sphingomyelinase - Sanofi; GZ-402665; Recombinant human acid sphingomyelinase - Sanofi; rhASM - Sanofi; Sphingomyelinase-C (synthetic human) - Sanofi; Synthetic human sphingomyelinase-C - Sanofi; XENPOZYME; XenpozymeLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Recombinant proteins; Sphingomyelin phosphodiesterases
- Mechanism of Action Sphingomyelin-phosphodiesterase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Niemann-Pick diseases
Most Recent Events
- 05 Mar 2024 Launched for Niemann-Pick diseases (In adolescents, In children, In adults) in United Kingdom, Cyprus, Italy, Austria, Germany (IV)
- 05 Mar 2024 National Institute for Health and Care Excellence (NICE) decides not to recommend olipudase alfa in Niemann-Pick diseases
- 10 Nov 2023 Pooled efficacy data from a phase-II/II ASCEND, phase I/II ASCEND-Peds and phase I trial in Niemann-Pick diseases presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)